Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Onkaido Therapeutics Inc.

Messenger RNA therapeutics for oncology

This article was originally published in Start Up

Executive Summary

Moderna Therapeutics says it has found ways to design, manufacture, formulate, and deliver mRNA so that it can instruct cells in different tissues and organs to make virtually any protein, intracellular or secreted. To begin commercializing drugs designed to make therapeutic proteins inside patients' own cells, Moderna has spun out Onkaido Therapeutics Inc. and funded it with $20 million and 15 oncology drug candidates, in the areas of apoptosis, central regulatory nodes, and immunotherapy.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts